Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.73 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.68 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438142 | 0.95 | EPHX2 (0.71) | HDAC1HDAC6ERCC1ERCC4HDAC3 | |
| SCHEMBL2924662 | 0.93 | HDAC6 (0.74) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL9416580 | 0.90 | HDAC6 (0.64) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL457082 | 0.88 | HDAC6 (0.79) | HDAC1HDAC6ERCC1ERCC4HDAC2 | |
| SCHEMBL29184442 | 0.86 | HDAC6 (0.76) | HDAC1HDAC6ERCC1ERCC4HDAC2 | |
| Hydrochloric Acid SCHEMBL3757721 | 0.86 | HDAC6 (0.76) | HDAC1HDAC6ERCC1ERCC4HDAC2 | |
| SCHEMBL10099575 | 0.85 | NR1H4 (0.84) | HDAC1HDAC6ERCC1ERCC4HDAC3 | |
| SCHEMBL2777733 | 0.85 | HDAC6 (0.72) | HDAC1HDAC6ERCC1ERCC4HDAC3 | |
| SCHEMBL28966141 | 0.84 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL9416590 | 0.84 | ALDH1A1 (0.59) | HDAC1HDAC6ERCC1ERCC4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014072903-A1 | NOVEL AMINOMETHYL-PHENOL DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-15 | — | — | WO | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| CN-101166726-A | Quinoline and quinoxaline derivatives as inhibitors of kinase enzyme activity | CHROMA THERAPEUTICS LTD (GB) | 2008-04-23 | — | — | CN | disclosed |
| EP-1633715-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | Pfizer Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| CN-1200915-C | Process for preparing organic compound | MITSUI CHEMICALS INC (JP) | 2005-05-11 | — | — | CN | disclosed |
| CN-1190441-C | Phosphine sulfide preparing process and use thereof | MITSUI CHEMICALS INC (JP) | 2005-02-23 | — | — | CN | disclosed |
| US-20040260039-A1 | Process for producing organic compound epoxy resin composition, cured article obtained from the epoxy resin, and semiconductor device obtained with epoxy resin | MITSUI CHEMICALS, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108676-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| EP-0972776-B1 | A phosphine sulfide, a manufacturing process therefor and a use thereof | MITSUI CHEMICALS INC (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-0950649-B1 | A process for preparing oxyalkylene derivatives in the presence of phosphine oxides | MITSUI CHEMICALS INC (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6153794-A | Phosphine sulfide, a manufacturing process therefor and use thereof | MITSUI CHEMICALS, INC. (JP) | 2000-11-28 | — | — | US | disclosed |
| US-6130346-A | ESTERIFICATION, CARBONATION, SULFONATION, ETHERIFICATION | MITSUI CHEMICALS, INC. (JP) | 2000-10-10 | — | — | US | disclosed |
| EP-0972776-A1 | A phosphine sulfide, a manufacturing process therefor and a use thereof | Mitsui Chemicals, Inc. (JP) | 2000-01-19 | — | — | EP | disclosed |
| CN-1235141-A | Process for preparing organic compound | MITSUI CHEMICALS INC (JP) | 1999-11-17 | — | — | CN | disclosed |
| EP-0950649-A1 | A process for preparing oxyalkylene derivatives in the presence of phosphine oxides | Mitsui Chemicals, Inc. (JP) | 1999-10-20 | — | — | EP | disclosed |
| US-4599151-A | ELECTROLYTIC | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1986-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CDK1, AURKC, CSNK1G3 | HDAC1 423/4885HDAC6 1980/4885ERCC1 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.